Ta Giang H, Leong Max K
Department of Chemistry, National Dong Hwa University, Hualien, Taiwan.
Front Pharmacol. 2024 Nov 26;15:1496630. doi: 10.3389/fphar.2024.1496630. eCollection 2024.
The clinical drug-drug interaction side-effects of Ritonavir, an ingredient in Paxlovid™, have been documented, highlighting the need to explore alternative administration methods for Nirmatrelvir, another drug in the Paxlovid™ combination. In this study, the skin permeability potential of Nirmatrelvir was assessed using various models. The prediction results suggest that Nirmatrelvir could be administrated via the transdermal route, offering a promising avenue to enhance the efficacy of anti-COVID-19 agents.
帕罗韦德™（Paxlovid™）中的成分利托那韦的临床药物相互作用副作用已有记录，这凸显了探索帕罗韦德™组合中的另一种药物奈玛特韦的替代给药方法的必要性。在本研究中，使用各种模型评估了奈玛特韦的皮肤渗透潜力。预测结果表明，奈玛特韦可以通过透皮途径给药，为提高抗新冠病毒药物的疗效提供了一条有前景的途径。
